000154704 001__ 154704
000154704 005__ 20190316234930.0
000154704 0247_ $$2doi$$a10.1371/journal.pone.0007431
000154704 022__ $$a1932-6203 000154704 02470$$2ISI$$a000271022300002 000154704 037__$$aARTICLE
000154704 245__ $$aCan survival prediction be improved by merging gene expression data sets? 000154704 269__$$a2009
000154704 260__ $$bPublic Library of Science$$c2009
000154704 336__ $$aJournal Articles 000154704 520__$$aBACKGROUND: High-throughput gene expression profiling technologies generating a wealth of data, are increasingly used for characterization of tumor biopsies for clinical trials. By applying machine learning algorithms to such clinically documented data sets, one hopes to improve tumor diagnosis, prognosis, as well as prediction of treatment response. However, the limited number of patients enrolled in a single trial study limits the power of machine learning approaches due to over-fitting. One could partially overcome this limitation by merging data from different studies. Nevertheless, such data sets differ from each other with regard to technical biases, patient selection criteria and follow-up treatment. It is therefore not clear at all whether the advantage of increased sample size outweighs the disadvantage of higher heterogeneity of merged data sets. Here, we present a systematic study to answer this question specifically for breast cancer data sets. We use survival prediction based on Cox regression as an assay to measure the added value of merged data sets. RESULTS: Using time-dependent Receiver Operating Characteristic-Area Under the Curve (ROC-AUC) and hazard ratio as performance measures, we see in overall no significant improvement or deterioration of survival prediction with merged data sets as compared to individual data sets. This apparently was due to the fact that a few genes with strong prognostic power were not available on all microarray platforms and thus were not retained in the merged data sets. Surprisingly, we found that the overall best performance was achieved with a single-gene predictor consisting of CYB5D1. CONCLUSIONS: Merging did not deteriorate performance on average despite (a) The diversity of microarray platforms used. (b) The heterogeneity of patients cohorts. (c) The heterogeneity of breast cancer disease. (d) Substantial variation of time to death or relapse. (e) The reduced number of genes in the merged data sets. Predictors derived from the merged data sets were more robust, consistent and reproducible across microarray platforms. Moreover, merging data sets from different studies helps to better understand the biases of individual studies and can lead to the identification of strong survival factors like CYB5D1 expression.
000154704 6531_ $$aGene Expression Profiling 000154704 6531_$$aGene Expression Regulation
000154704 700__ $$aYasrebi, Haleh 000154704 700__$$aSperisen, Peter
000154704 700__ $$aPraz, Viviane 000154704 700__$$0244404$$aBucher, Philipp$$g113607
000154704 773__ $$j4$$k10$$qe7431$$tPloS one
000154704 8564_ $$s660284$$uhttps://infoscience.epfl.ch/record/154704/files/journal.pone.0007431.pdf$$yPublisher's version$$zn/a
000154704 909C0 $$0252244$$pGR-BUCHER$$xU11780 000154704 909CO$$ooai:infoscience.tind.io:154704$$pSV$$particle$$qGLOBAL_SET 000154704 917Z8$$x182396
000154704 937__ $$aEPFL-ARTICLE-154704 000154704 973__$$aEPFL$$rREVIEWED$$sPUBLISHED
000154704 980__ aARTICLE